Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry - Wikidata - awgldk - TriplyDB

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry

http://www.wikidata.org/entity/Q33683158

about

Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease Fabry's disease discovered with chance urinary mulberry cells: a case report.Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia.Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.Fabry disease: the many faces of a single disorder.The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease Fibrosis: a key feature of Fabry disease with potential therapeutic implications Renal complications of Fabry disease in children Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.Potential role of vitamin D deficiency on Fabry cardiomyopathy.Interdisciplinary approach towards female patients with Fabry disease.Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature?Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.Analytic Considerations for Repeated Measures of eGFR in Cohort Studies of CKD.Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors Is it or is it not a pathogenic mutation? Is it or is it not the podocyte?Fabry disease: dose matters.A case of Fabry nephropathy with histological features of oligonephropathy.Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.Variable phenotypic presentations of renal involvement in Fabry disease: a case series.Major Organic Involvement in Women with Fabry Disease in Argentina.Fabry disease

P2860

Q21261394-375BBAB0-3526-4045-811D-93121E5AE98F Q28730130-BC83CD4E-3815-4D98-ABD1-386DDF2F6BF4 Q33628288-9C587719-F858-46D6-BA61-88EB2B2D243E Q33645550-5E5893C1-0851-4D46-BC32-7DA62EC6D559 Q33858105-DB44FA3F-48B2-40DD-8131-CB26AAE287A6 Q33886219-8A6C535F-E2AC-4DB4-8E00-07C59F97EDE2 Q34794444-C709561A-B20F-4761-A4D0-0C918B1E664B Q35009083-797DAFDF-3B09-430B-80B8-B81051153C70 Q35587768-7AC9D5B5-E705-473F-9EF4-BC213230A3CF Q35608422-23B5A3A7-2566-4443-8BC6-6BFCF15ED91B Q35692435-51CD2F4F-056D-433E-821E-92D2508813DA Q35788989-5BA9E702-2DA9-4538-96EA-E18583D04B37 Q36475780-B8F8C1CD-2CE7-4B66-A358-4B2474F4BDDA Q36808226-D0AAF314-2CC1-45A1-B6CB-6C24DC9C6D70 Q37113004-4FB78AB9-6637-4B76-B86C-DCFA8A122493 Q37265117-6117254A-5C39-475D-BB9F-F9187A4C924C Q37534497-1C632F01-D4C8-4188-AC76-0A5320A12965 Q37686030-FF09DFD7-DE92-4E8D-AA6B-D1545093BAAF Q37952232-ACAB32A8-CD9E-4A9C-80FA-DDE979ED3D2F Q38152826-46125690-9F41-46A4-8ADA-BF99B38797D2 Q38184922-EBD739B5-0232-4DB3-9473-61BE11FE6341 Q38230252-F999A98F-3D2D-42CF-951A-017415C4548D Q38656498-ECD3C4FF-7894-4F8E-8D56-A55824A6D717 Q41200738-C58DC2C5-D777-400A-A634-533B510261AA Q41861331-6E046F02-FA3E-4066-8970-5F4F1476AE9D Q42389941-AACF8C97-27DD-4BB2-AA2A-DDDC5CF4133B Q43516814-E59F0551-89F7-41C8-9D60-40DBA95AD48F Q44063760-A70ADE6C-B00C-42CB-845D-89B4698F2545 Q46881710-035AC101-A133-4975-B599-8AC598BCA48D Q51289036-8CADC0E1-0E7D-4A01-BB50-67B5E703093F Q54945741-C3CCB2BF-804F-4BDE-A861-319A034BDBF9 Q55492022-BEACF6F0-7D09-45AB-82AA-F029B9CAAC1A Q56905945-9B53E678-B70C-486F-A868-F2E19B304ECC

P2860

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry

http://www.wikidata.org/entity/Q33683158

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Prognostic indicators of renal ...... y data from the Fabry Registry

@ast

Prognostic indicators of renal ...... y data from the Fabry Registry

@en

type

label

Prognostic indicators of renal ...... y data from the Fabry Registry

@ast

Prognostic indicators of renal ...... y data from the Fabry Registry

@en

prefLabel

Prognostic indicators of renal ...... y data from the Fabry Registry

@ast

Prognostic indicators of renal ...... y data from the Fabry Registry

@en

P1433

Q33683158-A9E4B9C1-B020-41BC-B167-989E27F5E7B7

P1476

Q33683158-EE455FC3-31B0-4E60-9DB9-6019804EDF23

P2093

Q33683158-1C9D6483-5BC2-4EAA-9A04-6F10DCCE599C

Q33683158-20D3CE08-01CE-46CB-B209-0ABFB7F22B28

Q33683158-2C30F12F-FD91-4FD9-A895-52266A4EC45C

Q33683158-385C759E-A4DD-4DC8-B60C-04AF4FEA674F

Q33683158-4398C153-5461-489F-9E8F-338DAFEAB0DA

Q33683158-4CB56A42-DB48-46F6-8965-356A1C8F4E65

Q33683158-56D9E98D-52CD-492A-9DAF-D02510A19CD7

Q33683158-708C4DD1-CA64-4BA8-8AE3-B7BF6DC15DE9

Q33683158-7F634558-0F61-4999-BEBC-E5718130260A

Q33683158-BA5DDAD4-B2B3-4FDE-9004-E35BBF2949C4

P2860

Q33683158-06575E54-5ED3-4EBE-9094-CB524530E21D

Q33683158-06CAC9A6-ECF1-49AB-A9D5-9C64258AD8D1

Q33683158-0BEC295F-F32F-4670-9AB7-E1AD3A065C41

Q33683158-2271A962-51BE-4653-A8E8-BEB98C095CB1

Q33683158-276DE84B-3C3E-43FC-A33A-C4D491F43EC7

Q33683158-33208A43-A23E-45D4-81A3-8C0075AE59CA

Q33683158-34DFD059-5894-4C1C-AB53-5D9CE979DE14

Q33683158-3BDEAFD4-9F96-4BA7-9374-8BA4FA172E65

Q33683158-5C564F74-FE24-43D7-98C0-F4D7EC824A66

Q33683158-65C1DF77-4EE1-4675-9947-3F2AF83BA145

P304

Q33683158-0640E85C-D679-4276-9500-6DB0B1E34297

P31

Q33683158-705B4345-0208-4EED-80A7-9B3447DC5F81

P356

Q33683158-B47406C6-B4DF-44D8-A803-BC23223A33F8

P433

Q33683158-28B138B7-86A7-4241-B88B-62147C286132

P478

Q33683158-866EA87E-4DF6-44AE-9E56-7B14D5593933

P50

Q33683158-616928C8-8503-4479-B136-8C75CCE668A1

Q33683158-A08E70CD-53BA-44FF-92AB-6E76CC673774

Q33683158-C6B73FD8-C9FC-4744-A16F-7BE0D91BE553

P577

Q33683158-A9594B6C-0646-4396-A877-64507635E05B

P5875

Q33683158-55C1AA4F-14F0-41E1-80C3-5D6DC7E75707

P698

Q33683158-C6C2443E-FACD-4A32-AC44-AD171B7689ED

P932

Q33683158-9A04DE47-4F42-4E5E-B3C7-26528EFC48F5

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Prognostic indicators of renal ...... y data from the Fabry Registry

@en

P2093

Andreas L Serra

http://www.w3.org/2001/XMLSchema#string

Bojan Vujkovac

http://www.w3.org/2001/XMLSchema#string

Bruno Cianciaruso

http://www.w3.org/2001/XMLSchema#string

Christoph Wanner

http://www.w3.org/2001/XMLSchema#string

Dana Beitner-Johnson

http://www.w3.org/2001/XMLSchema#string

David G Warnock

http://www.w3.org/2001/XMLSchema#string

Gabor E Linthorst

http://www.w3.org/2001/XMLSchema#string

László Maródi

http://www.w3.org/2001/XMLSchema#string

Michael Mauer

http://www.w3.org/2001/XMLSchema#string

Renzo Mignani

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

A new equation to estimate glomerular filtration rate

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

Assessing kidney function--measured and estimated glomerular filtration rate.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

P304

2220-2228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.04340510

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

João Paulo Oliveira

Dominique P Germain

P577

2010-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46124345

http://www.w3.org/2001/XMLSchema#string

P698

20813854

http://www.w3.org/2001/XMLSchema#string

P932

2994083

http://www.w3.org/2001/XMLSchema#string